Log in

NYSE:GMED - Globus Medical Stock Price, Forecast & News

$41.58
-1.52 (-3.53 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$40.00
Now: $41.58
$42.63
50-Day Range
$35.06
MA: $47.01
$56.65
52-Week Range
$33.41
Now: $41.58
$60.15
Volume843,729 shs
Average Volume1.52 million shs
Market Capitalization$4.15 billion
P/E Ratio27.18
Dividend YieldN/A
Beta1.08
Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its spine product portfolio includes a range of implant and surgical approach options that could be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers imaging, navigation, and robotic assisted surgery technology solutions, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures. In addition, it provides regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. Further, the company offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems. Additionally, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Read More
Globus Medical logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP37957720
Phone610-930-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$785.37 million
Cash Flow$2.15 per share
Book Value$14.05 per share

Profitability

Net Income$155.21 million

Miscellaneous

Employees2,000
Market Cap$4.15 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive GMED News and Ratings via Email

Sign-up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.


Globus Medical (NYSE:GMED) Frequently Asked Questions

How has Globus Medical's stock been impacted by COVID-19 (Coronavirus)?

Globus Medical's stock was trading at $38.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GMED stock has increased by 9.3% and is now trading at $41.58. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Globus Medical?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Globus Medical.

When is Globus Medical's next earnings date?

Globus Medical is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Globus Medical.

How were Globus Medical's earnings last quarter?

Globus Medical Inc (NYSE:GMED) posted its earnings results on Thursday, February, 20th. The medical device company reported $0.49 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.52 by $0.03. The medical device company earned $211.67 million during the quarter, compared to analysts' expectations of $211.11 million. Globus Medical had a net margin of 19.76% and a return on equity of 13.01%. The business's revenue for the quarter was up 8.0% compared to the same quarter last year. During the same period last year, the business earned $0.43 earnings per share. View Globus Medical's earnings history.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical updated its FY20 earnings guidance on Thursday, February, 20th. The company provided EPS guidance of $1.82 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.88. The company issued revenue guidance of $850 million, compared to the consensus revenue estimate of $852.63 million.

What price target have analysts set for GMED?

8 Wall Street analysts have issued 12 month target prices for Globus Medical's stock. Their forecasts range from $46.00 to $67.00. On average, they anticipate Globus Medical's stock price to reach $59.63 in the next twelve months. This suggests a possible upside of 43.4% from the stock's current price. View analysts' price targets for Globus Medical.

Has Globus Medical been receiving favorable news coverage?

Media stories about GMED stock have been trending somewhat negative recently, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Globus Medical earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the medical device company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutGlobus Medical.

Are investors shorting Globus Medical?

Globus Medical saw a increase in short interest in March. As of March 13th, there was short interest totaling 2,885,800 shares, an increase of 54.3% from the February 27th total of 1,870,000 shares. Based on an average daily volume of 583,600 shares, the short-interest ratio is presently 4.9 days. Approximately 3.8% of the company's stock are short sold. View Globus Medical's Current Options Chain.

Who are some of Globus Medical's key competitors?

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include AbbVie (ABBV), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Alibaba Group (BABA), Walt Disney (DIS), Intuitive Surgical (ISRG), Intel (INTC), NVIDIA (NVDA), Bausch Health Companies (BHC) and Novartis (NVS).

Who are Globus Medical's key executives?

Globus Medical's management team includes the following people:
  • Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 52)
  • Mr. David M. Demski, CEO & Director (Age 61)
  • Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 48)
  • Mr. David D. Davidar, Co-Founder & Director (Age 53)
  • Mr. Daniel T. Scavilla, CFO, Exec. VP & Chief Commercial Officer (Age 54)

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by many different retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (6.93%), State Street Corp (2.55%), GW&K Investment Management LLC (1.41%), Standard Life Aberdeen plc (1.31%), AXA (1.23%) and AQR Capital Management LLC (1.21%). Company insiders that own Globus Medical stock include Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz, James R Tobin, Kelly Huller and Steven Payne. View institutional ownership trends for Globus Medical.

Which major investors are selling Globus Medical stock?

GMED stock was sold by a variety of institutional investors in the last quarter, including Nuance Investments LLC, Janus Henderson Group PLC, AQR Capital Management LLC, Renaissance Technologies LLC, Marathon Asset Management LLP, Retirement Systems of Alabama, GW&K Investment Management LLC, and Pembroke Management LTD. Company insiders that have sold Globus Medical company stock in the last year include David D Davidar, and Kelly Huller. View insider buying and selling activity for Globus Medical.

Which major investors are buying Globus Medical stock?

GMED stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, AXA, Panagora Asset Management Inc., Goldman Sachs Group Inc., Madison Asset Management LLC, Nuveen Asset Management LLC, First Trust Advisors LP, and Prudential Financial Inc.. View insider buying and selling activity for Globus Medical.

How do I buy shares of Globus Medical?

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $41.58.

How big of a company is Globus Medical?

Globus Medical has a market capitalization of $4.15 billion and generates $785.37 million in revenue each year. The medical device company earns $155.21 million in net income (profit) each year or $1.68 on an earnings per share basis. Globus Medical employs 2,000 workers across the globe. View additional information about Globus Medical.

What is Globus Medical's official website?

The official website for Globus Medical is http://www.globusmedical.com/.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]


MarketBeat Community Rating for Globus Medical (NYSE GMED)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  480 (Vote Outperform)
Underperform Votes:  390 (Vote Underperform)
Total Votes:  870
MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: Death Cross

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel